Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Dallas, TX
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Houston, TX
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
San Antonio, TX
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
West Jordan, UT
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
West Jordan, UT
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Norfolk, VA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Norfolk, VA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Roanoke, VA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Roanoke, VA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Seattle, WA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Seattle, WA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Bridgeport, WV
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Bridgeport, WV
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Sandy Springs, GA
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Sandy Springs, GA
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Research Site
mi
from
Angers,
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Research Site
mi
from
Angers,
Click here to add this to my saved trials
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated:  8/2/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Observational Study to Estimate the Effectiveness of Biologics When Treating Plaque Psoriasis
A Prospective, Observational Study to Estimate the Proportion of Subjects With Plaque Psoriasis Who Achieve Complete Clearance on Biologics
Status: Enrolling
Updated: 8/2/2017
Clinical Research Facility
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Status: Enrolling
Updated:  8/21/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Texting Atopic Dermatitis Patients to Optimize Learning and EASI Scores
Status: Enrolling
Updated: 8/21/2017
Columbia University Medical Center / Department of Dermatology
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
New York, NY
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
New York, NY
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Portland, OR
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Portland, OR
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Johnston, RI
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Johnston, RI
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Dallas, TX
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Dallas, TX
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Seattle, WA
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Seattle, WA
Click here to add this to my saved trials
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated:  9/12/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
A Randomized, Double-Blind, Placebo-Controlled, Phase IIa Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
Status: Enrolling
Updated: 9/12/2017
GSK Investigational Site
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated:  9/18/2017
University Medicine and Dentistry of New Jersey
mi
from
New Brunswick, NJ
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated: 9/18/2017
University Medicine and Dentistry of New Jersey
mi
from
New Brunswick, NJ
Click here to add this to my saved trials
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated:  9/18/2017
NYU School of Medicine
mi
from
New York, NY
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated: 9/18/2017
NYU School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated:  9/18/2017
Mt. Sinai School of Medicine
mi
from
New York, NY
Open-Label,Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC1004 in Subjects With Severe Plaque Type Psoriasis
Open-Label, Single-Arm Pilot Study to Evaluate the Pharmacodynamics, Pharmacokinetics, Safety, and Preliminary Efficacy of CC10004 in Subjects With Severe Plaque Type Psoriasis
Status: Enrolling
Updated: 9/18/2017
Mt. Sinai School of Medicine
mi
from
New York, NY
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Anniston, AL
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Anniston, AL
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Orlando, FL
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Orlando, FL
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
High Point, NC
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
High Point, NC
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Duncansville, PA
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Duncansville, PA
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Duncansville, PA
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
San Antonio, TX
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
North Hollywood, CA
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
North Hollywood, CA
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Atlanta, GA
Click here to add this to my saved trials
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated:  9/19/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Pharmacokinetic Study to Evaluate the Effect of a Single Dose of Guselkumab (CNTO 1959) on CYP 450 Enzyme Activities After Subcutaneous Administration in Participants With Psoriasis
A Phase 1, Open-label, Drug Interaction Study to Evaluate the Effect of Guselkumab (CNTO 1959) on Cytochrome P450 Enzyme Activities Following a Single Subcutaneous Administration in Subjects With Moderate to Severe Plaque-type Psoriasis
Status: Enrolling
Updated: 9/19/2017
Clinical Research Facility
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Dermatology Research Associate
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
UCSD Division of Dermatology
mi
from
San Diego, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
UCSD Division of Dermatology
mi
from
San Diego, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Univ of Calif, San Francisco
mi
from
San Francisco, CA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Univ of Calif, San Francisco
mi
from
San Francisco, CA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Colorado Anschutz Cancer Pavilion
mi
from
Aurora, CO
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Ameriderm Research
mi
from
Ormond Beach, FL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Ameriderm Research
mi
from
Ormond Beach, FL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Olympian Clinical Research
mi
from
Tampa, FL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Olympian Clinical Research
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Northwestern University Feinberg School of Medicine
mi
from
Chicago, IL
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Iowa Healthcare; Dermatology
mi
from
Iowa City, IA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Iowa Healthcare; Dermatology
mi
from
Iowa City, IA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Massachusetts General Hospital
mi
from
Boston, MA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Somerset Skin Centre
mi
from
Troy, MI
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Somerset Skin Centre
mi
from
Troy, MI
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Washington University-Dermatology
mi
from
Saint Louis, MO
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Washington University-Dermatology
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Sadick Research Group
mi
from
New York, NY
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Sadick Research Group
mi
from
New York, NY
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Oregon Health & Science University, Department of Dermatology
mi
from
Portland, OR
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Oregon Health & Science University, Department of Dermatology
mi
from
Portland, OR
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
University of Texas Medical School in Houston
mi
from
Houston, TX
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
University of Texas Medical School in Houston
mi
from
Houston, TX
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Dermatology Clinical Research Center of San Antonio
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated:  9/28/2017
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
A Study of Lebrikizumab in Participants With Persistent Moderate to Severe Atopic Dermatitis
A Phase II, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety and Efficacy of Lebrikizumab in Patients With Persistent Moderate to Severe Atopic Dermatitis That is Inadequately Controlled by Topical Corticosteroids
Status: Enrolling
Updated: 9/28/2017
St George Dermatology and Skin Cancer Centre
mi
from
Kogarah,
Click here to add this to my saved trials